Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

NCT06798909 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus (CMV)
Kidney Transplant; Complications
Kidney Diseases

Interventions

DRUG: Valganciclovir (Pre-emptive CMV Therapy)
DRUG: Valganciclovir CMV Prophylaxis

Sponsor

University of California, San Francisco

Collaborators

[object Object]